ClinicalTrials.gg
CompletedNCT02046616Updated Apr 13, 2018Results posted

A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

A Phase 3 interventional study of Tocilizumab and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 27 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-13.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
133
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
41st of 110
133 · median 97
Started
2014
with 8 others
Phase 3
65 of 110
none open now
Registered
84th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 41st largest by enrollment, is one of 9 that started in 2014, is one of 65 in phase 3, and was the 84th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This Phase IIIb, open-label, single-arm study will evaluate the safety, efficacy, and tolerability of SC tocilizumab (RoActemra/Actemra) in monotherapy or in combination with methotrexate or other non-biologic DMARDs in participants with active RA who are naive to tocilizumab. Participants will receive tocilizumab 162 milligrams (mg) subcutaneously weekly (QW) for 24 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active RA according to the revised ACR (1987) criteria or EULAR/ACR (2010) criteria
  • Moderate to severe RA with a DAS28-ESR score >3.2 points
  • Inadequate response and/or intolerance to MTX or other non-biologic DMARDs and/or where MTX or other non-biologic DMARDs are inappropriate
  • Oral (less than or equal to [\</=] 10 mg per day prednisolone or equivalent) and nonsteroidal anti-inflammatory drugs (NSAIDs) permitted if on stable dose regimen for greater than or equal to [>/=] 4 weeks prior to baseline
  • Permitted non-biologic DMARDs allowed if at stable dose for >/=4 weeks prior to baseline
  • Receiving treatment on an outpatient basis, not including tocilizumab
  • Agreement to use reliable means of as defined by protocol, among females of and males with female partners of childbearing potential

Exclusion criteria

Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline
  • Rheumatic disease other than RA
  • Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis
  • Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16
  • Prior history of or current inflammatory joint disease other than RA
  • Exposure to tocilizumab or any other biologic DMARDs at any time prior to baseline
  • Treatment with any agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening
  • Intra-articular or parenteral within 4 weeks prior to baseline
  • History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
  • Evidence of serious concomitant disease or disorder
  • Known active current or history of recurrent infection
  • Any major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening
  • Active tuberculosis requiring treatment within the previous 3 years
  • Positive for or
  • History of or current active primary or secondary immunodeficiency
  • Pregnant or lactating women
  • Neuropathies or other conditions that might interfere with pain evaluation
  • Inadequate hematologic, renal, or liver function
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    Tocilizumab Alone or Combined with Methotrexate or Other DMARD

    All participants will receive tocilizumab as a single fixed dose (monotherapy) or in combination with methotrexate or other non-biologic DMARDs, irrespective of body weight, for 24 weeks.

    Drug: Tocilizumab · Drug: Methotrexate · Drug: Non-Biologic DMARDs

Interventions

  • Tocilizumab 162 mg will be administered subcutaneously QW.

    Also known as: RoActemra, Actemra

  • Methotrexate dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.

  • DrugNon-Biologic DMARDs

    Participants will receive non-biologic DMARDs (same non-biologic DMARD that participant was receiving at time of study entry). Dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12

    CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in Disease Activity Score 28 (DAS28)-Erythrocyte Sedimentation Rate (ESR) Score

    DAS28-ESR was based on TJC, SJC, PGA of disease activity, and laboratory-derived ESR. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA of disease activity was scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity. The total DAS28-ESR score was transformed to a single score range of 0-10, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24

  2. Percentage of Participants With American College of Rheumatology (ACR) Response

    ACR response was assessed on the basis of percent improvement (20% for ACR20, 50% for ACR50, 70% for ACR70) in both TJC and SJC as well as at least three of the following: physician assessment of disease activity, PGA of disease activity, PGA of pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), and either ESR or C-reactive protein level. TJC and SJC were taken as the number of tender and swollen joints, out of 68 and 66 assessed joints, respectively. PGA and physician assessments were scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity or pain. HAQ-DI was scored using participant responses to 20 questions assessing activities of daily living (ADLs), with total score scale of 0-3, where higher scores indicate increased functional disability. The percentage of participants meeting criteria for each level of ACR response was reported.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 24

  3. Percentage of Participants With European League Against Rheumatism (EULAR) Response

    EULAR response was assessed by change from baseline and absolute DAS28-ESR score. EULAR response classification was as follows: Good (change \>1.2 with absolute score \</=3.2), Moderate (change \>1.2 with absolute score \>3.2 or change \>0.6 with absolute score \</=5.1), None (change \</=0.6 or absolute score \>5.1). DAS28-ESR was based on TJC, SJC, and PGA of disease activity, and laboratory-derived ESR. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA of disease activity was scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity. The total DAS28-ESR score was transformed to a single score range of 0-10, where higher scores indicate increased disease activity. The percentage of participants meeting criteria for each level of EULAR response was reported.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 24

  4. Change From Baseline in CDAI at Weeks 2, 4, 8, 16, 20, and 24

    CDAI was derived as the sum of the following: TJC, SJC, PGA of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 mm and rounded to the nearest cm on a VAS, where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.

    Time frame: Baseline and Weeks 2, 4, 8, 16, 20, 24

  5. Change From Baseline in Simplified Disease Activity Index (SDAI)

    SDAI was derived as the sum of the following: TJC, SJC, PGA of disease activity, physician assessment of disease activity, and laboratory-derived C-reactive protein level. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 mm and rounded to the nearest cm on a VAS, where higher scores indicate greater perceived disease activity. The total SDAI score range was 0-86, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24

  6. Change From Baseline in TJC

    TJC was taken as the number of tender joints out of 28 assessed joints.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24

  7. Change From Baseline in SJC

    SJC was taken as the number of swollen joints out of 28 assessed joints.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24

  8. Percentage of Participants With At Least One Adverse Event Leading to Dosage Modification

    The percentage of participants with at least one adverse event leading to dose/frequency reduction or temporary dose hold was reported.

    Time frame: Baseline up to Week 24

  9. Number of Participants With Neutralizing Anti-Tocilizumab Antibodies

    Participants were evaluated for the presence of anti-tocilizumab antibodies. Confirmatory assays were performed in the case of a positive screen assay result.

    Time frame: Baseline to FU Week 8 (up to 32 weeks overall)

  10. Tocilizumab Concentration

    Tocilizumab concentration was determined, averaged among all participants, and expressed in micrograms per milliliter (mcg/mL).

    Time frame: Predose (30 minutes) at baseline; Weeks 12, 24; and FU Week 8 (up to 32 weeks overall)

  11. Soluble Interleukin-6 Receptor (sIL-6R) Concentration

    sIL-6R concentration was determined, averaged among all participants, and expressed in nanograms per milliliter (ng/mL).

    Time frame: Predose (30 minutes) at baseline; Weeks 12, 24; and FU Week 8 (up to 32 weeks overall)

  12. Change From Baseline in Patient Global Assessment of Disease Activity According to VAS

    PGA of disease activity was scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24

  13. Change From Baseline in Patient Global Assessment of RA-Related Pain According to VAS

    PGA of RA-related pain was scored 0-100 mm on a VAS, where higher scores indicate greater perceived pain. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA-related pain.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24

  14. Change From Baseline in HAQ-DI Score

    HAQ-DI consisted of 20 questions assessing ADLs in 8 domains (dress/groom, arise, eat, walk, reach, grip, hygiene) with each item rated 0 (no difficulty) to 3 (unable to do). The highest score recorded for any question in a domain determined the score for that domain, unless assistance was required. The total HAQ-DI score was the sum of domain scores divided by the number of domains answered/scored, for a single score range of 0-3, where higher scores indicate increased functional disability. Change from baseline was averaged among all participants. Negative values indicate improvement in ability to perform ADLs.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24

  15. Compliance With Treatment According to Percentage of Injections Administered

    Participants were provided with diary cards to record home injections. Compliance with treatment was calculated individually for each participant as the actual number of injections as a percentage of the planned number of injections (up to the point of discontinuation for those who discontinued study treatment prematurely) and then averaged among all participants.

    Time frame: Baseline up to Week 24

  16. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score

    FACIT-F consisted of 40 questions/statements assessing chronic illness therapy with special emphasis on fatigue over the past 7 days, with each item rated 0 (not at all) to 4 (very much). During score calculations, negatively-worded item scales (e.g., "I have a lack of energy") were reversed so that higher scores indicated more favorable conditions. The total FACIT-F score was the sum of all item scores and ranged 0-160, and the brief FACIT-F score was the sum of 13 item scores and ranged 0-52, where higher scores indicate greater well-being. Change from baseline was averaged among all participants. Positive values indicate improvement in well-being.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24

07

Results

Posted Apr 13, 2018

Participant flow

24-Week Treatment Period
Participant flow — 24-Week Treatment Period
MilestoneTocilizumab Alone or Combined With Methotrexate or Other DMARD
Started133
Completed114
Not completed19
Withdrew: Anaphylaxis/serious hypersensitivity1
Withdrew: Any other adverse event13
Withdrew: Insufficient therapeutic response1
Withdrew: Physician decision3
Withdrew: Other1
8-Week FU Period
Participant flow — 8-Week FU Period
MilestoneTocilizumab Alone or Combined With Methotrexate or Other DMARD
Started114
Completed113
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Week 12

CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12
units on a scaleTocilizumab Alone or Combined With Methotrexate or Other DMARD
Baseline24.9 ± 10.5
Change at Week 12-16.6 ± 12.1
SecondaryChange From Baseline in Disease Activity Score 28 (DAS28)-Erythrocyte Sedimentation Rate (ESR) Score

DAS28-ESR was based on TJC, SJC, PGA of disease activity, and laboratory-derived ESR. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA of disease activity was scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity. The total DAS28-ESR score was transformed to a single score range of 0-10, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score 28 (DAS28)-Erythrocyte Sedimentation Rate (ESR) Score
units on a scaleTocilizumab Alone or Combined With Methotrexate or Other DMARD
Baseline5.0 ± 1.1
Change at Week 2-1.4 ± 1.0
Change at Week 4-2.1 ± 1.1
Change at Week 8-2.8 ± 1.3
Change at Week 12-2.9 ± 1.5
Change at Week 16-3.2 ± 1.4
Change at Week 20-3.3 ± 1.4
Change at Week 24-3.3 ± 1.4
SecondaryPercentage of Participants With American College of Rheumatology (ACR) Response

ACR response was assessed on the basis of percent improvement (20% for ACR20, 50% for ACR50, 70% for ACR70) in both TJC and SJC as well as at least three of the following: physician assessment of disease activity, PGA of disease activity, PGA of pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), and either ESR or C-reactive protein level. TJC and SJC were taken as the number of tender and swollen joints, out of 68 and 66 assessed joints, respectively. PGA and physician assessments were scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity or pain. HAQ-DI was scored using participant responses to 20 questions assessing activities of daily living (ADLs), with total score scale of 0-3, where higher scores indicate increased functional disability. The percentage of participants meeting criteria for each level of ACR response was reported.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 24
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology (ACR) Response
percentage of participantsTocilizumab Alone or Combined With Methotrexate or Other DMARD
ACR20, Week 225.2
ACR20, Week 451.5
ACR20, Week 870.4
ACR20, Week 1270.8
ACR20, Week 1682.5
ACR20, Week 2077.2
ACR20, Week 2478.1
ACR50, Week 28.7
ACR50, Week 422.3
ACR50, Week 846.4
ACR50, Week 12 (n=120)51.7
ACR50, Week 1665.8
ACR50, Week 2064.9
ACR50, Week 2463.2
ACR70, Week 20.8
ACR70, Week 48.5
ACR70, Week 824.0
ACR70, Week 1230.0
ACR70, Week 1644.2
ACR70, Week 2042.1
ACR70, Week 2447.4
SecondaryPercentage of Participants With European League Against Rheumatism (EULAR) Response

EULAR response was assessed by change from baseline and absolute DAS28-ESR score. EULAR response classification was as follows: Good (change \>1.2 with absolute score \</=3.2), Moderate (change \>1.2 with absolute score \>3.2 or change \>0.6 with absolute score \</=5.1), None (change \</=0.6 or absolute score \>5.1). DAS28-ESR was based on TJC, SJC, and PGA of disease activity, and laboratory-derived ESR. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA of disease activity was scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity. The total DAS28-ESR score was transformed to a single score range of 0-10, where higher scores indicate increased disease activity. The percentage of participants meeting criteria for each level of EULAR response was reported.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 24
Reported as:
Number · percentage of participants
Percentage of Participants With European League Against Rheumatism (EULAR) Response
percentage of participantsTocilizumab Alone or Combined With Methotrexate or Other DMARD
Week 2, Good29.1
Week 2, Moderate47.2
Week 2, None23.6
Week 4, Good51.2
Week 4, Moderate39.5
Week 4, None9.3
Week 8, Good78.4
Week 8, Moderate (n=125)16.8
Week 8, None4.8
Week 12, Good (n=119)78.2
Week 12, Moderate16.0
Week 12, None5.9
Week 16, Good87.5
Week 16, Moderate9.2
Week 16, None3.3
Week 20, Good86.7
Week 20, Moderate8.8
Week 20, None4.4
Week 24, Good87.7
Week 24, Moderate9.6
Week 24, None2.6
SecondaryChange From Baseline in CDAI at Weeks 2, 4, 8, 16, 20, and 24

CDAI was derived as the sum of the following: TJC, SJC, PGA of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 mm and rounded to the nearest cm on a VAS, where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.

Time frame:
Baseline and Weeks 2, 4, 8, 16, 20, 24
Reported as:
Mean · units on a scale
Change From Baseline in CDAI at Weeks 2, 4, 8, 16, 20, and 24
units on a scaleTocilizumab Alone or Combined With Methotrexate or Other DMARD
Change at Week 2-6.2 ± 8.4
Change at Week 4-10.5 ± 9.8
Change at Week 8-15.7 ± 11.0
Change at Week 16-18.8 ± 11.5
Change at Week 20-18.9 ± 11.7
Change at Week 24-19.0 ± 11.7
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI)

SDAI was derived as the sum of the following: TJC, SJC, PGA of disease activity, physician assessment of disease activity, and laboratory-derived C-reactive protein level. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 mm and rounded to the nearest cm on a VAS, where higher scores indicate greater perceived disease activity. The total SDAI score range was 0-86, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
Reported as:
Mean · units on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI)
units on a scaleTocilizumab Alone or Combined With Methotrexate or Other DMARD
Baseline35.76 ± 20.71
Change at Week 2-15.37 ± 16.71
Change at Week 4-20.32 ± 19.24
Change at Week 8-25.89 ± 20.88
Change at Week 12-26.19 ± 23.21
Change at Week 16-29.03 ± 21.15
Change at Week 20-28.47 ± 21.26
Change at Week 24-28.93 ± 20.93
SecondaryChange From Baseline in TJC

TJC was taken as the number of tender joints out of 28 assessed joints.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
Reported as:
Mean · tender joints
Change From Baseline in TJC
tender jointsTocilizumab Alone or Combined With Methotrexate or Other DMARD
Baseline8.8 ± 5.2
Change at Week 2-2.1 ± 5.8
Change at Week 4-3.5 ± 6.1
Change at Week 8-5.8 ± 6.3
Change at Week 12-5.5 ± 7.1
Change at Week 16-6.7 ± 6.9
Change at Week 20-6.7 ± 6.5
Change at Week 24-7.1 ± 5.8
SecondaryChange From Baseline in SJC

SJC was taken as the number of swollen joints out of 28 assessed joints.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
Reported as:
Mean · swollen joints
Change From Baseline in SJC
swollen jointsTocilizumab Alone or Combined With Methotrexate or Other DMARD
Baseline6.8 ± 5.5
Change at Week 2-2.3 ± 4.3
Change at Week 4-3.1 ± 4.7
Change at Week 8-4.8 ± 5.1
Change at Week 12-5.3 ± 5.3
Change at Week 16-5.9 ± 5.2
Change at Week 20-6.0 ± 5.4
Change at Week 24-5.4 ± 5.3
SecondaryPercentage of Participants With At Least One Adverse Event Leading to Dosage Modification

The percentage of participants with at least one adverse event leading to dose/frequency reduction or temporary dose hold was reported.

Time frame:
Baseline up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With At Least One Adverse Event Leading to Dosage Modification
percentage of participantsTocilizumab Alone or Combined With Methotrexate or Other DMARD
Dose/Frequency Reduced Due to Adverse Event18.80
Dose Held Due to Adverse Event27.07
SecondaryNumber of Participants With Neutralizing Anti-Tocilizumab Antibodies

Participants were evaluated for the presence of anti-tocilizumab antibodies. Confirmatory assays were performed in the case of a positive screen assay result.

Time frame:
Baseline to FU Week 8 (up to 32 weeks overall)
Reported as:
Number · participants
Number of Participants With Neutralizing Anti-Tocilizumab Antibodies
participantsTocilizumab Alone or Combined With Methotrexate or Other DMARD
Number of Participants With Neutralizing Anti-Tocilizumab Antibodies1
SecondaryTocilizumab Concentration

Tocilizumab concentration was determined, averaged among all participants, and expressed in micrograms per milliliter (mcg/mL).

Time frame:
Predose (30 minutes) at baseline; Weeks 12, 24; and FU Week 8 (up to 32 weeks overall)
Reported as:
Mean · mcg/mL
Tocilizumab Concentration
mcg/mLTocilizumab Alone or Combined With Methotrexate or Other DMARD
Baseline0.6 ± 0.3
Week 1247.4 ± 28.1
Week 2448.0 ± 27.2
FU Week 832.8 ± 19.3
SecondarySoluble Interleukin-6 Receptor (sIL-6R) Concentration

sIL-6R concentration was determined, averaged among all participants, and expressed in nanograms per milliliter (ng/mL).

Time frame:
Predose (30 minutes) at baseline; Weeks 12, 24; and FU Week 8 (up to 32 weeks overall)
Reported as:
Mean · ng/mL
Soluble Interleukin-6 Receptor (sIL-6R) Concentration
ng/mLTocilizumab Alone or Combined With Methotrexate or Other DMARD
Baseline37.0 ± 12.7
Week 12509.4 ± 138.7
Week 24520.2 ± 156.4
FU Week 8166.0 ± 203.5
SecondaryChange From Baseline in Patient Global Assessment of Disease Activity According to VAS

PGA of disease activity was scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
Reported as:
Mean · mm
Change From Baseline in Patient Global Assessment of Disease Activity According to VAS
mmTocilizumab Alone or Combined With Methotrexate or Other DMARD
Baseline53.2 ± 21.1
Change at Week 2-6.8 ± 18.6
Change at Week 4-20.3 ± 21.3
Change at Week 8-24.6 ± 25.8
Change at Week 12-30.3 ± 25.5
Change at Week 16-32.3 ± 23.9
Change at Week 20-32.2 ± 27.1
Change at Week 24-34.3 ± 24.8
SecondaryChange From Baseline in Patient Global Assessment of RA-Related Pain According to VAS

PGA of RA-related pain was scored 0-100 mm on a VAS, where higher scores indicate greater perceived pain. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA-related pain.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
Reported as:
Mean · mm
Change From Baseline in Patient Global Assessment of RA-Related Pain According to VAS
mmTocilizumab Alone or Combined With Methotrexate or Other DMARD
Baseline54.8 ± 22.1
Change at Week 2-9.1 ± 20.8
Change at Week 4 (n=128)-22.5 ± 24.4
Change at Week 8-28.9 ± 26.6
Change at Week 12-32.8 ± 27.5
Change at Week 16-35.6 ± 25.9
Change at Week 20-35.0 ± 26.7
Change at Week 24-37.8 ± 26.3
SecondaryChange From Baseline in HAQ-DI Score

HAQ-DI consisted of 20 questions assessing ADLs in 8 domains (dress/groom, arise, eat, walk, reach, grip, hygiene) with each item rated 0 (no difficulty) to 3 (unable to do). The highest score recorded for any question in a domain determined the score for that domain, unless assistance was required. The total HAQ-DI score was the sum of domain scores divided by the number of domains answered/scored, for a single score range of 0-3, where higher scores indicate increased functional disability. Change from baseline was averaged among all participants. Negative values indicate improvement in ability to perform ADLs.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
Reported as:
Mean · units on a scale
Change From Baseline in HAQ-DI Score
units on a scaleTocilizumab Alone or Combined With Methotrexate or Other DMARD
Baseline (n=133)1.2 ± 0.6
Change at Week 2-0.1 ± 0.4
Change at Week 4-0.3 ± 0.5
Change at Week 8-0.5 ± 0.5
Change at Week 12-0.5 ± 0.6
Change at Week 16-0.6 ± 0.6
Change at Week 20-0.6 ± 0.6
Change at Week 24-0.6 ± 0.6
SecondaryCompliance With Treatment According to Percentage of Injections Administered

Participants were provided with diary cards to record home injections. Compliance with treatment was calculated individually for each participant as the actual number of injections as a percentage of the planned number of injections (up to the point of discontinuation for those who discontinued study treatment prematurely) and then averaged among all participants.

Time frame:
Baseline up to Week 24
Reported as:
Mean · percentage of injections
Compliance With Treatment According to Percentage of Injections Administered
percentage of injectionsTocilizumab Alone or Combined With Methotrexate or Other DMARD
Compliance With Treatment According to Percentage of Injections Administered86.78 ± 23.04
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score

FACIT-F consisted of 40 questions/statements assessing chronic illness therapy with special emphasis on fatigue over the past 7 days, with each item rated 0 (not at all) to 4 (very much). During score calculations, negatively-worded item scales (e.g., "I have a lack of energy") were reversed so that higher scores indicated more favorable conditions. The total FACIT-F score was the sum of all item scores and ranged 0-160, and the brief FACIT-F score was the sum of 13 item scores and ranged 0-52, where higher scores indicate greater well-being. Change from baseline was averaged among all participants. Positive values indicate improvement in well-being.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score
units on a scaleTocilizumab Alone or Combined With Methotrexate or Other DMARD
Brief Score, Baseline (n=133)32.9 ± 11.1
Brief Score, Change at Week 23.4 ± 6.9
Brief Score, Change at Week 45.7 ± 8.3
Brief Score, Change at Week 86.6 ± 8.0
Brief Score, Change at Week 127.6 ± 7.8
Brief Score, Change at Week 167.9 ± 9.7
Brief Score, Change at Week 208.0 ± 9.1
Brief Score, Change at Week 248.4 ± 8.5
Total Score, Baseline106.8 ± 23.6
Total Score, Change at Week 26.9 ± 14.0
Total Score, Change at Week 413.0 ± 16.6
Total Score, Change at Week 815.1 ± 16.2
Total Score, Change at Week 1217.1 ± 16.2
Total Score, Change at Week 1618.0 ± 20.1
Total Score, Change at Week 2018.6 ± 19.8
Total Score, Change at Week 2420.1 ± 19.3

Adverse events

Collected over Baseline up to FU Week 8 (up to 32 weeks overall). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab Alone or Combined With Methotrexate or Other DMARD—12/133 (9%)120/133 (90.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventTocilizumab Alone or Combined With Methotrexate or Other DMARD
HypertensionVascular disorders2/133
PneumoniaInfections and infestations2/133
Acute psychosisPsychiatric disorders1/133
Anaphylactic reactionImmune system disorders1/133
Back painMusculoskeletal and connective tissue disorders1/133
ConstipationGastrointestinal disorders1/133
Gastrooesophageal reflux diseaseGastrointestinal disorders1/133
HeadacheNervous system disorders1/133
Infectious pleural effusionInfections and infestations1/133
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/133
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTocilizumab Alone or Combined With Methotrexate or Other DMARD
NasopharyngitisInfections and infestations20/133
HypertensionVascular disorders17/133
NauseaGastrointestinal disorders11/133
Upper respiratory tract infectionInfections and infestations10/133
RashSkin and subcutaneous tissue disorders10/133
Alanine aminotransferase increasedInvestigations9/133
HeadacheNervous system disorders9/133
PruritusSkin and subcutaneous tissue disorders8/133
Injection site erythemaGeneral disorders7/133
Neutrophil count decreasedInvestigations7/133

Baseline characteristics

Intent-to-Treat (ITT) Set: all participants who were treated with at least one dose of SC tocilizumab.

Age, Continuous
Age, Continuous(years)Tocilizumab Alone or Combined With Methotrexate or Other DMARD
Mean55.9 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab Alone or Combined With Methotrexate or Other DMARD
Female108
Male25
08

Study locations

27 sites
  • Aalborg Universitetshospital Nord, Reumatologisk Afdeling
    Alborg, 9000, Denmark
  • Glostrup Hospital, Reumatologisk Afdeling, Ambulatoriet
    Glostrup, 2600, Denmark
  • Gentofte Hospital, Medicinsk Afd. C, Klinik for Gigt- og Rygsygdomme
    Hellerup, 2900, Denmark
  • Holbæk Sygehus, Medicinsk Afd., Reumatologisk Amb.15-2
    Holbæk, 4300, Denmark
  • Sjællands Universitetshospital, Køge; Reumatologisk Afdeling
    Køge, 4600, Denmark
  • Odense Universitetshospital, Reumatologisk Afdeling C, Ambulatoriet
    Odense, 5000, Denmark
  • Svendborg Sygehus, Reumatologisk Ambulatorium
    Svendborg, 5700, Denmark
  • Helsinki University Central Hospital; Rheumatology Clinic
    Helsinki, 00290, Finland
  • Kiljavan Lääketutkimus Oy
    Hyvinkää, 05800, Finland
  • Central Hospital of Pohjois-Karjala; Outpatient Clinic of Rheumatology
    Joensuu, 80210, Finland
  • Keski-Suomen Keskussairaala; Sisätautien Klinikka
    Jyväskylä, 40620, Finland
  • Lappeenranta Central Hospital; Outpatient Clinic of Internal Medicine
    Lappeenranta, 53130, Finland
  • Oulu University Hospital; Rheumatology
    Oulu, 90220, Finland
  • Haukeland Universitetssykehus; Revmatologisk Avdeling
    Bergen, 5053, Norway
  • Drammen sykehus Vestre Viken HF, Revmatologisk avd.
    Drammen, 3004, Norway
  • Diakonhjemmet; Reumatolgisk Avdeling
    Oslo, 0370, Norway
  • St. Olavs Hospital; Revmatologisk avdeling
    Trondheim, 7030, Norway
  • Ålesund Sykehus; Revmatologisk Avdeling
    Ålesund, 6017, Norway
  • Länssjukhuset Ryhov; Ortoped- och Reumatolog kliniken
    Jönköping, 551 85, Sweden
  • Uni Hospital Linkoeping; Dept. of Rheumatology
    Linkoeping, 58185, Sweden
  • Skånes Universitetssjukhus Lund; Reumatologkliniken
    Lund, 221 85, Sweden
  • Skånes Universitetssjukhus Malmö; Reumatologkliniken
    Malmo, 205 02, Sweden
  • Örebro Uni Hospital; Rheumatology
    Oerebro, 70185, Sweden
  • Simrishamns Sjukhus
    Simrishamn, 272 81, Sweden
  • Karolinska Sjukhuset; Reumatologkliniken D2-1
    Stockholm, 171 76, Sweden
  • Akademiska sjukhuset, Reumatologkliniken
    Uppsala, 75185, Sweden
  • Västmanlands sjukhus Västerås, Reumatologkliniken
    Västerås, 72189, Sweden
09

References and documents

Publications

  • Hammer HB, Jensen Hansen IM, Jarvinen P, Leirisalo-Repo M, Ziegelasch M, Agular B, Terslev L. Rheumatoid arthritis patients with predominantly tender joints rarely achieve clinical remission despite being in ultrasound remission. Rheumatol Adv Pract. 2021 May 14;5(2):rkab030. doi: 10.1093/rap/rkab030. eCollection 2021. PubMed 34131623 ↗
  • Hammer HB, Hansen I, Jarvinen P, Leirisalo-Repo M, Ziegelasch M, Agular B, Terslev L. Major reduction of ultrasound-detected synovitis during subcutaneous tocilizumab treatment: results from a multicentre 24 week study of patients with rheumatoid arthritis. Scand J Rheumatol. 2021 Jul;50(4):262-270. doi: 10.1080/03009742.2020.1845394. Epub 2021 Jan 19. PubMed 33464147 ↗
  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Devenport J, Petho-Schramm A. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. Rheumatology (Oxford). 2019 Jun 1;58(6):1056-1064. doi: 10.1093/rheumatology/key393. PubMed 30649524 ↗
  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Petho-Schramm A. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. doi: 10.1093/rheumatology/kex443. Erratum In: Rheumatology (Oxford). 2018 Jun 1;57(6):1129. doi: 10.1093/rheumatology/key116. PubMed 29244149 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Sep 2016, 27 months.

Results were first posted in Apr 2018, 1 year 7 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 27 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2014
First posted
Jan 28, 2014
StartActual
May 28, 2014
Primary completionActual
Sep 13, 2016
CompletionActual
Sep 13, 2016
Results first posted
Apr 13, 2018
Last update
Apr 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02046616
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 28, 2014
Start date
May 28, 2014
Primary completion
Sep 13, 2016
Completion
Sep 13, 2016
Results posted
Apr 13, 2018
Last update
Apr 13, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion